Opal Capital’s Cogent Biosciences COGT Stock Holding History

Opal Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,961	Closed	-$264K	–	155
2025 Q4	$264K	Buy	+6,961	New	+$196K	0.07%	146

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Opal Capital's COGT Position: Q1 2026 in Review

Opal Capital sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 6,961 shares — an estimated $264K sold.

Opal Capital first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $264K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Opal Capital reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
Opal Capital sold 6,961 Cogent Biosciences shares in Q1 2026, an estimated $264K.
Opal Capital first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
Opal Capital's Cogent Biosciences position peaked at $264K in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.